Antitumor efficacy of the in situ cancer vaccine of DSF/Cu and IR was immune effector CD8+ and CD4+ T cell-dependent and modulated by suppressive cytokines in the TME and peripheral blood of mice. This evidence concerns the gene CD8A and cancer.